Publishing: May 2021 | Report Code: LS10400 | Available Format: PDF
The global cardiac bio-implant devices market is witnessing growth due to high incidences of cardiovascular diseases and increasing geriatric population. The massive unexplored cardiac bio-implant devices market in the emerging economies is creating ample opportunities for the growth of the global cardiac bio-implant devices market, at a considerable rate in the coming years. The advanced research and development activities and new product developments by the major players are supporting the demand for cost effective and efficient cardiac bio-implant devices, thus fuelling the growth of the global cardiac bio-implant devices market.
Cardiovascular disease refers to the disease of heart or blood vessels, which are mainly caused due to blood clot or cholesterol deposit inside an artery. Cardiovascular diseases are of several types including coronary heart disease, rheumatic heart disease, peripheral arterial disease, congenital heart disease, deep vein thrombosis, and pulmonary embolism. Some of the major risk-leading habits towards cardiovascular diseases are high blood pressure, high blood cholesterol, diabetes, smoking and obesity. Moreover, alcohol, lack of exercise and poor nutrition may also cause heart diseases. According to the WHO, cardiovascular diseases are the major cause of all deaths worldwide. The organization also reported that 17.5 million people died from cardiovascular diseases in 2012, representing 31% of all deaths globally.
Cardiac bio-implant devices are the medical devices used for the treatment of cardiovascular diseases. Cardiac bio-implants have unique compatibility with body tissues or blood. The different implantable cardiovascular devices available are pacemakers, heart valves, cardioverter defibrillators and stents.
The global cardiac bio-implant devices market is segmented into pacing devices, stents and related implants, and structural cardiac implants. The pacing devices segment comprises implantable cardiac pacemakers (ICPs), implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy devices (CRTs) and pacing accessories. The stents and related implants segment includes coronary stents, peripheral stents and stent-related implants; whereas, the structural cardiac implants segment comprises heart valves and accessories, insertable loop recorders/implantable heart monitors, and ventricular-assist devices.
Some of the factors driving the growth of the global cardiac bio-implant devices market are increasing healthcare expenditure, aging population and growing incidences of cardiovascular diseases. In addition, the technological advancements and high investments for the development and manufacturing of cardiac bio-implant devices are fueling the growth of the global cardiac bio-implant devices. However, high cost of cardiac bio-implant devices, complications associated with the usage of these devices and stringent regulatory requirements for the approval of cardiac bio-implant devices are some of the factors, restraining the growth of the global cardiac bio-implant devices market to some extent.
Geographically, North America leads the global cardiac bio-implant devices market due to high healthcare expenditure, aging population and high prevalence of cardiovascular diseases. In addition, the technological advancement and high investment by major players for the development of cardiac bio-implant devices are fueling the growth of the cardiac bio-implant devices market in North America. Asia-Pacific is the fastest growing region in the global cardiac bio-implant devices market, driven by improving healthcare infrastructure, growing healthcare expenditure and high prevalence of cardiovascular diseases. Moreover, the Asia-Pacific cardiac bio-implant devices market is growing rapidly due increasing research and development activities and increasing awareness about cardiac bio-implant devices among patients and healthcare providers in emerging economies, such as India and China.
The key players operating in the global cardiac bio-implant devices market are St. Jude Medical Inc., Medtronic, Boston Scientific Corporation, Johnson & Johnson Services Inc., Sorin Group, Abbott and Edwards Lifesciences Corporation.
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws